Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
90Y-DOTATATE
- Development stage
- Phase 3
- Lead developer
- Erasmus MC
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous, Intra-arterial
01
Overview
90Y-DOTATATE is a radiolabeled peptide used in peptide receptor radionuclide therapy (PRRT) for the treatment of neuroendocrine tumors (NETs). It consists of the somatostatin analogue Tyr3-octreotate conjugated to the chelator DOTA and labeled with the beta-emitting radioisotope yttrium-90. The drug binds with high affinity to somatostatin receptor subtype 2 (SSTR2), which is overexpressed on many NET cells. Upon binding, it delivers targeted radiation to tumor cells, leading to DNA damage and cell death while sparing most normal tissues. Its longer beta range compared to other isotopes makes it particularly effective for treating larger tumors[1][5]. Clinical studies have shown disease stabilization or partial remission in a significant proportion of patients with advanced or metastatic NETs[5][2].
- Brand names
- ItraPol
- Other names
- Yttrium-90 DOTATATEYttrium90 DOTATATEYttrium 90 DOTATATE[90Y]DOTA-Tyr3-octreotate
02
Targets
SSTR2 (Somatostatin receptor type 2)SSTR3 (Somatostatin receptor 3)SSTR5 (Somatostatin receptor 5)
Beyond the preview
Go deeper on 90Y-DOTATATE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 90Y-DOTATATE.